Hospital Acquired Infections (HAI) Diagnostics Market - By Product (Reagents, Analyzers), By Test Type (Traditional Diagnostic Test, Molecular Diagnostic Assay, Immunoassays, Mass Spectrometry), By Infection Type, By End-use, & Forecast, 2023 – 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationHospital Acquired Infections (HAI) Diagnostics Market Size
Hospital Acquired Infections Diagnostics Market size was valued at around USD 4.5 billion in 2022 and is estimated to register around 8% CAGR between 2023 and 2032. Healthcare facilities are increasingly prioritizing infection control practices to prevent and reduce hospital acquired infections rates. This focus has led to the adoption of advanced diagnostics for early detection and surveillance of HAIs, facilitating precise intervention and prevention strategies. Molecular diagnostics, such as PCR and next-generation sequencing have improved the sensitivity and specificity of HAI detection.
Imagine you're at the hospital with a nasty infection. You want to know what's causing it right away so you can get the right treatment. Rapid diagnostic tests can help! These tests are like detectives that quickly search for the culprit bacteria or virus. They're easy to use and give results in a flash. Another cool thing is that doctors can do these tests right in the hospital room. This means you don't have to wait for days for results, and your doctor can make decisions faster. It's like having a speedy crime solver on the case! This is especially great in emergency rooms and other critical care areas, where time is of the essence. And let's not forget about cost. Hospitals want to save money, so they're looking for affordable and practical tests that still give reliable results. With all these technological advances, growing awareness about infections, and government support, companies are developing new ways to diagnose hospital infections better and faster. This means more accurate diagnoses, fewer infections, and healthier patients. It's a win-win for everyone!
The hospital acquired infections (HAI) diagnostics includes diagnostic tests and devices used for the detection and monitoring of infections that are acquired in healthcare settings such as hospitals, clinics, and long-term care facilities. HAI also known as nosocomial infections, that patients acquire during the course of receiving healthcare treatment for other conditions.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Hospital Acquired Infections Diagnostics Market Size in 2022 | USD 4.5 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 8% |
| 2032 Value Projection | USD 10.2 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 451 |
| Segments covered | Product, Test Type, Infection Type, End-use and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Unfortunately, many people in low-income countries are unaware of how infections can spread in hospitals. This is a big problem because it affects how much money can be made in the healthcare market. Hospitals in these countries often have limited resources, such as money, staff, and equipment. This makes it hard to put in place strong infection control programs and educate healthcare workers and patients about hospital-acquired infections (HAIs). Healthcare workers in low-income countries may not have access to training programs that teach them how to prevent and control HAIs. Additionally, HAIs may not be given as much attention or resources in these settings, which means that people are less aware of them.
COVID-19 Impact
COVID-19 turned the healthcare world upside down, and hospital infection testing was no exception. At first, everything was about COVID-19. Hospitals and testing companies scrambled to deal with the pandemic, and routine testing for other infections like those acquired in hospitals (HAIs) took a backseat. Resources like staff, lab space, and supplies were all focused on COVID-19 testing. But as we learned more about COVID-19 and testing capacity increased, the healthcare industry started to get back to dealing with HAIs. The pandemic had made it clear how important it was to stop infections from spreading in hospitals, and effective testing is key to that. In fact, COVID-19 even gave a boost to new technologies and ideas in the HAI testing market.
Hospital Acquired Infections Diagnostics Market Trends
Imagine a bustling hospital where the fight against infections rages on. Technology has stepped up to the plate, armed with cutting-edge tools that make finding these sneaky invaders faster and more precise than ever before. Molecular diagnostics, like PCR and NAATs, have become the secret weapons in this battle. They're like super-sleuths, sniffing out the DNA fingerprints of nasty bugs and spotting them within hours. This quick response means doctors can catch infections early on, before they cause havoc. And for those pesky antibiotic-resistant critters, these tests can sound the alarm, helping hospitals track down outbreaks before they spread like wildfire. But that's not all! Next-Generation Sequencing (NGS) has entered the arena, like a microscope on steroids. It can read the entire genetic code of these invaders, revealing their secrets and helping us understand how they spread and become resistant. It's like a blueprint for cracking the code and figuring out the best ways to stop them in their tracks. These technological marvels are changing the game in infection control, giving hospitals the tools they need to keep patients safe and healthy.
Imagine having a doctor's office right at your bedside! That's what point-of-care testing devices (POCT) are all about. These handy devices are like tiny labs that can give you test results in minutes, right on the spot. This means no more waiting or sending samples to a faraway lab. With POCT, doctors can quickly check for infections in a snap. This can help catch those nasty bugs early on, before they become full-blown infections. Even better, powerful computers are now helping doctors use all that patient data to predict the risk of infections and even spot outbreaks before they happen. These amazing advances in infection detection are like giving superpowers to doctors. They can make sure you get the right treatment faster, which can lead to better health outcomes for you. Plus, it saves time and money for hospitals and clinics, making healthcare a little smoother for everyone.
Hospital Acquired Infections (HAI) Diagnostics Market Analysis
Imagine a market for tools used to diagnose infections in hospitals. This market can be divided into two main types of toolsreagents and analyzers. In 2022, reagents took the lead, accounting for the largest share of the market. Why? Because they're essential for detecting infections accurately and on time. In hospitals, it's crucial to identify infections early on for effective treatment. Companies that make reagents are always trying to create new ones that are super sensitive and specific. This means they can detect even tiny amounts of infectious agents that cause infections in hospitals. This helps doctors make accurate diagnoses quickly and reliably, even when the infection levels are low. These reagents are often used in automated diagnostic systems. These systems make testing more efficient and reduce the risk of errors. They can handle a lot of samples at once, which is helpful for screening patients or in busy hospital labs.
In HAI diagnostics tests, reagents can be modified to target specific pathogens commonly associated with hospital-acquired infections such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. difficile), or multidrug-resistant Gram-negative bacteria. These reagents can be used in various diagnostic methods including polymerase chain reaction (PCR), immunoassays, or nucleic acid amplification tests (NAATs) to identify the presence of these pathogens or their associated biomarkers. As a result, by utilizing reagents in HAI diagnostics tests, healthcare professionals can quickly and accurately identify infections, initiate appropriate treatments, and implement infection control measures to prevent the spread of HAIs in healthcare settings.
The hospital acquired infections diagnostics market has different types of tests, such as the classic test, molecular test, rapid test, special machine test, and so on. In 2022, the rapid tests were the most popular, bringing in about 1.7 billion US dollars. Rapid tests help doctors figure out what's causing infections in the hospital. They can tell what germs are causing the infection, how the person's immune system is responding, and what the best treatment is. The most popular rapid tests for hospital acquired infections are the ELISA test, the PCR test, the IFA test, and the blood test.
Imagine you're like a detective trying to track down hidden clues in your body. That's exactly what ELISA and serological tests do when it comes to healthcare. ELISA is like a blood detective that sniffs out specific proteins called antibodies or antigens that our immune system makes when it's fighting off a bug. By finding these proteins, ELISA can tell us if a person has been exposed to a particular germ or if they're currently battling an infection. Serological tests are another blood-detective team that searches for antibodies. They help us understand if a patient has ever met a certain bug before. If they find antibodies, it means that the patient has encountered that bug either in the past or right now. These tests are like detectives cracking the case of healthcare-associated infections, or HAIs, which are infections people can pick up in the hospital. By finding clues in the blood, healthcare pros can diagnose HAIs quickly and start treatment right away. This helps stop the infection from spreading and keeps patients safe.
Hospitals have different ways to test for infections. This market is divided into different types of testsUrinary tract infections (UTIs)This is when bacteria get into your urinary system, which includes your bladder, kidneys, and urethra. Surgical site infections (SSIs) This is when an infection develops in the area where surgery was done. Respiratory infectionsThis is any infection in your lungs, airways, or nose. Bloodstream infections This is when bacteria or other germs get into your blood. Gastrointestinal infectionsThis is when you have an infection in your digestive system, like diarrhea or food poisoning. Other infections This includes any other types of infections that hospitals can test for. In 2022, the most common type of hospital infection test was for UTIs. This made up about 1.4 billion U.S. dollars in the market. UTIs are one of the most common infections people get in hospitals. Tests for UTIs are important because they can find and treat infections early on. This helps doctors give patients the right treatment right away.
Early identification can prevent the infection from spreading and causing complications. UTIs can be caused by various pathogens, including bacteria, viruses, and fungi. Diagnostics tests such as urine culture and sensitivity testing can accurately identify the specific pathogen causing the infection. Some UTIs can be recurrent, especially in healthcare settings. Diagnostics tests can help identify underlying causes or risk factors contributing to recurrent infections such as anatomical abnormalities or indwelling catheters. Conclusively, diagnostics tests for UTIs offer several advantages including early detection, accurate pathogen identification, antibiotic susceptibility testing, prevention of recurrent infections, and infection control among others. As a result, these tests play a vital role in the management and prevention of UTIs acquired in hospitals.
Based on end-use, the hospital acquired infections diagnostics market is segmented as hospitals, diagnostic laboratories, research institute, and others. The hospitals segment held significant share in 2022 and is projected to reach more than USD 4.8 billion by the end of 2032. The soaring use of novel immunodiagnostic tests in hospital settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of kits for performing these tests with proven accuracy is set to drive product preference in hospitals.
Growing prevalence of hospital acquired infections and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment growth positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals. As a result, accessibility to an effective diagnosis coupled with the rising prevalence of hospital acquired infections and associated conditions will boost the patient visits to hospitals, thereby propelling the segment revenue growth.
U.S. hospital acquired infections diagnostics market with a significant market share in 2022 and is anticipated to expand at a considerable pace to reach around USD 4.2 billion by 2032. This dominant market share is attributable to the increasing prevalence of HAI, emphasis on infection control & prevention, and technological advancements among others. Healthcare-associated infections remain a significant concern in the U.S., leading to increased demand for diagnostic tests that can quickly and accurately detect and identify pathogens responsible for infections.
Hospital Acquired Infections (HAI) Diagnostics Market Share
Some of the major market players operating in the hospital acquired infections diagnostics market are
- Abbott Laboratories
- Bayer
- Becton Dickinson And Company
- Biomérieux
- Danaher Corporation
- Ecolab
Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
Hospital Acquired Infections (HAI) Diagnostics Industry News
- In February 2023, Thermo Fisher Scientific partnered with Mylab Discovery Solutions to launch RT- PCR kits for infectious diseases in India. As per the company, highly accurate and effective diagnostic tests such as RT-PCR will help in significant reduction of the burden of these diseases in India. Such strategic moves will assist Thermo Fisher to develop high quality molecular diagnostics kits for patients around the world.
- In September 2021, Roche launched diagnostic test panels to detect respiratory illnesses. The three new respiratory test panels can be run together or alone using one patient sample. It uses a use a real-time PCR nucleic acid amplification method to detect specific DNA sequences obtained after extraction. This product launch helped the company to expand the availability of these tests beyond CE markets in the future.
Hospital acquired infections (HAI) diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (Units) from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Product
- Reagents
- Analyzers
By Test Type
- Traditional Diagnostic Test
- Molecular Diagnostic Assay
- Immunoassays
- Mass Spectrometry
- Others
By Infection Type
- Urinary Tract Infections (UTIs)
- Surgical Site Infections (SSIs)
- Respiratory Infections
- Bloodstream Infections
- Gastrointestinal Infections
- Others
By End-use
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Sweden
- The Netherlands
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Indonesia
- Philippines
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Iran
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy